EcoDrugPlus

Potassium Voltage-Gated Channel Subfamily H Member 2

Ensembl ID : ENSBBBG00000014939
Gene Symbol: KCNH2
1 Cross references
253 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 2

Ensembl ID : ENSBBBG00000018060
Gene Symbol: KCNQ2
3 Cross references
250 Possible Orthologues:

Potassium Voltage-Gated Channel Subfamily Q Member 5

Ensembl ID : ENSBBBG00000012198
Gene Symbol: KCNQ5
3 Cross references
200 Possible Orthologues:

Presenilin 1

Ensembl ID : ENSBBBG00000001581
Gene Symbol: PSEN1
3 Cross references
202 Possible Orthologues:

Presenilin 2

Ensembl ID : ENSBBBG00000012223
Gene Symbol: PSEN2
3 Cross references
205 Possible Orthologues:

Presenilin Enhancer, Gamma-Secretase Subunit

Ensembl ID : ENSBBBG00000006064
Gene Symbol: PSENEN
3 Cross references
185 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme

Ensembl ID : ENSBBBG00000011715
Gene Symbol: LOC104990413
2 Cross references
305 Possible Orthologues:

Primary Amine Oxidase, Liver Isozyme-Like

Ensembl ID : ENSBBBG00000006982
Gene Symbol: LOC104990779
2 Cross references
305 Possible Orthologues:

Primary Amine Oxidase, Lung Isozyme-Like

Ensembl ID : ENSBBBG00000011659
Gene Symbol: LOC104990417
2 Cross references
302 Possible Orthologues:

Progesterone Receptor

Ensembl ID : ENSBBBG00000024770
Gene Symbol: PGR
2 Cross references
194 Possible Orthologues:

Prostaglandin D2 Receptor

Ensembl ID : ENSBBBG00000010775
Gene Symbol: PTGDR
1 Cross references
118 Possible Orthologues:

Prostaglandin D2 Receptor 2

Ensembl ID : ENSBBBG00000005589
Gene Symbol: PTGDR2
1 Cross references
205 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).